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Guidelines for the diagnosis and management of asthma: a look at 
the key differences between BTS/SIGN and NICE  
 
John White, James Paton, Robert Niven, Hilary Pinnock 
On behalf of the British Thoracic Society 
 
The British Thoracic Society first produced a guideline on asthma and its management in 
1990. The first collaborative guideline with the Scottish Intercollegiate Guideline Network 
(SIGN) using evidence-based medicine methodology was published in 2003 (1). It has since 
become a mainstay of asthma management across the UK and beyond, with updates 
published regularly every 18 to 24 months. The latest BTS/SIGN guideline for the 
management of asthma was published in 2016 (2).  Both BTS and SIGN are committed to 
continuing updates with the next update planned for publication in 2019.  
 
Following publication of NICE Guidelines for diagnosis and monitoring, and for management 
of asthma (3, 4, 5) there are now two if not three national guidelines, for England at least, 
with some (apparently) striking differences. This statement considers the similarities and 
differences to assist clinical colleagues in the care of people with asthma. 
 
The evidence base considered by the BTS/SIGN and NICE guideline development groups is 
broadly the same for each guideline, but the methodology used to produce 
recommendations is significantly different: 
- SIGN methodology is a multidisciplinary clinically-led process which employs robust 
critical appraisal of the literature, coupled with consideration of pragmatic studies to 
ensure that guidelines provide clinically-relevant recommendations; 
- NICE methodology overlays critical appraisal of the literature with health economic 
modelling, with interpretation supported by advice from a multidisciplinary 
Guideline Development Group. 
 
These different processes have resulted in some discrepancies in recommendations made 
by BTS/SIGN and NICE.  This article seeks to provide some context to these differences in 
the key areas of: 
 
1. Diagnosis 
2. Pharmacological management 
- Treatment at diagnosis 
- The introduction of leukotriene receptor antagonists (LTRA) after low dose inhaled 
corticosteroids (ICS) 
- Maintenance and reliever therapy (MART) 
- Treatment beyond combined inhaler therapy 
- Some other issues in managing asthma in children  
 
The BTS/SIGN guideline also provides recommendations for important aspects of asthma 
management that are not addressed within NICE guidelines. These include guidance on 
 2 
 
inhaler devices, the management of acute asthma attacks in both adults and children, the 
management of difficult asthma, guidance on asthma in adolescents, in pregnant women 
and on occupational factors 
 
Diagnosis 
 
A series of recent reports have raised concerns about both over- and under- diagnosis of 
asthma (6, 7, 8) a key objective of both guidelines was to clarify the evidence and suggest 
approaches to improve clinical practice. 
 
There are many similarities between the NICE and BTS/SIGN recommendations for achieving 
an accurate diagnosis of asthma.  Both agree that no one symptom, sign, or test is 
diagnostic and the predictive value of diagnostic tests is influenced by the context, the 
reference test used, and the thresholds applied.  Both guidelines recommend that in the 
absence of unequivocal evidence of asthma, a diagnosis should be ‘suspected’ and that 
initiation of treatment (typically inhaled steroids) should be monitored carefully and the 
diagnosis reviewed if there is no objective benefit. Once a diagnosis is made, both BTS/SIGN 
and NICE guidelines emphasise the importance of recording the basis on which the 
diagnosis was made. 
 
NICE and BTS/SIGN offer algorithms, both of which are derived from evidence, but neither 
of which have prospective evidence to support them. In the case of NICE this was derived 
from health economic modelling of the diagnostic test data. NICE report that, in its pilot 
study in seven practices, its algorithm could be completed in 55% of patients with suspected 
asthma; a diagnosis of asthma was confirmed in 25% of cases; with 20% reaching no 
diagnosis despite completing the algorithm. (9)     
 
BTS/SIGN used the same diagnostic test evidence, but also explicitly searched for pragmatic 
studies reporting evaluation of diagnostic programmes and, in discussion with the clinical 
guideline development group members, derived a ‘good practice’ algorithm. The key 
difference between the approaches is that BTS/SIGN has adopted the terminology of 
probabilities as resonating with clinical practice (10).  
x This allows for the possibility that there will be people at high probability of asthma 
in whom a ‘monitored initiation of treatment’ is appropriate without necessarily 
awaiting further investigation.  An example of a ‘high probability’ scenario is the 
patient presenting with typical symptoms who has had a documented acute attack 
(with symptoms, chest signs and peak flow confirmation of the attack).  This is not 
recognised as a strategy for making a diagnosis by NICE, but it is reflected in the 
assumption underpinning the NICE economic modelling that 'a patient with a false 
negative diagnosis after working through the algorithm will be correctly re-
diagnosed after an exacerbation’ (10). 
x The diagnostic approach outlined in the BTS/SIGN ‘intermediate probability of 
asthma’ includes the same diagnostic tests as the NICE algorithm, but (in the 
absence of pragmatic evidence) is not prescriptive about the best order in which to 
perform them. 
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Both guidelines highlight the importance of a taking a detailed history, but the ‘structured 
clinical assessment’ of BTS/SIGN is broader than the ‘initial clinical assessment’ of NICE 
incorporating background information from the clinical record such as confirmed wheeze or 
a peak flow reading from a previous consultation, or risk factors for an alternative diagnosis. 
BTS/SIGN suggest that existing evidence of atopic status (blood eosinophils, skin prick 
testing, IgE) may influence the probability of asthma, but agree with NICE that they should 
not be considered as ‘diagnostic tests’; their key value may prove to be in establishing 
phenotypes of asthma or identifying triggers that may inform management (11).  
 
Spirometry is positioned as pivotal by both guidelines, but both caution that it is not useful 
for ruling out asthma because the sensitivity is low, especially in primary care populations 
(only 27% of people diagnosed as having asthma in the NICE feasibility work had obstructive 
spirometry which is similar to the estimate in BTS/SIGN of ‘a quarter having obstructive 
spirometry’). Both guidelines acknowledge that the forced expiratory volume in one 
second/forced vital capacity (FEV1/FVC) ratio changes with age. BTS/SIGN therefore 
recommends use of lower limit of normal (LLN) for FEV1/FVC ratio to avoid under-diagnosis 
in children and over-diagnosis in the elderly.  NICE acknowledges the advantages of using 
LLN (especially in children) and suggests it should be used ‘if the value is available’, though 
specifically uses the fixed ratio of 70% as the threshold for proceeding to bronchodilator 
reversibility (5). Figure 1 illustrates the significant limitations of the fixed ratio cut-off of 70% 
in children and the importance of using the LLN for defining airways obstruction (12). This is 
well illustrated in a recent report by Murray et al of the FEV1/FVC ratio in 71 children with 
current asthma. The mean FEV1/FVC ratio was 84% with only 2 children <70% (13).  
 
 
 
Figure 1 Predicted FEV1/FVC ratio and lower limit of normal in healthy females of different 
ethnicity GLI. 
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Reproduced from:  Quanjer PH, Stanojevic S, Stocks J, Cole TJ. GLI-2012 All-Age Multi-Ethnic Reference Values 
for Spirometry (Figure 16) www.ers-education.org/lrmedia/2012/pdf/266696.pdf  
under CC BY-NC 2.0. 
Both NICE and BTS/SIGN guidelines agree that Fractional Exhaled Nitric Oxide (FeNO) can be 
used as a surrogate marker of eosinophilic airway inflammation (14) with variable 
sensitivity/specificity for predicting asthma (15, 16). On this basis, NICE positions FeNO 
prominently in the algorithm in all adults and most children over 5 years with suspected 
asthma.  In the absence of evidence to inform its position within diagnostic algorithms, 
BTS/SIGN lists FeNO as a potentially useful test, specifically highlighting its role in the 
investigation of people with an intermediate probability of asthma and without spirometric 
evidence of obstruction or reversibility.    
 
Both guidelines suggest considering the development of diagnostic hubs (for NICE this is to 
‘achieve economies of scale’) (3).  The pragmatic ‘implementation’ evidence gathered by 
BTS/SIGN suggested that this was a model used in some countries which might be 
appropriate in some contexts to ‘streamline pathways for tests not available or 
inappropriate in primary care’.  
 
Both NICE and BTS/SIGN recommend further research on diagnostic accuracy of objective 
tests; BTS/SIGN also highlights the need for prospective evidence on the implementation of 
diagnostic algorithms encompassing clinical assessment as well as objective tests. 
 
Pharmacological management 
 
Treatment at diagnosis for adults (t17 years) and children 5 to 16 years 
 
The 2016 BTS/SIGN guideline recommends initiation of treatment with low dose ICS, making 
it explicit that patients should not be given short-acting beta-agonists (SABA) alone (except 
in the few with very occasional short-lived wheeze). This was a major revision from the 
previously recognised steps 1-5 model of the earlier BTS/SIGN guidelines, which had been in 
place for years.  
 
The motive for the change came following the National Review of Asthma Deaths (NRAD) 
(17) which demonstrated that a proportion of these deaths occurred in patients only 
treated with SABA and highlighted this as an important preventable factor.  
This change underlines the fundamental importance of a preventer strategy and has been 
widely welcomed. It has also brought the UK into line with Scandinavian guidance and 
practice, which has resulted in reduced mortality through early and focussed preventer 
strategies. (18) 
 
The NICE Guideline for the management of asthma has not followed this lead, still 
advocating the use of SABA alone in its algorithm though it is noteworthy that the detailed 
commentary reports this should only be prescribed for a small minority of patients (4).  For 
many, however, this will seem a retrograde step and has the potential to encourage 
continued over-reliance on SABA.  
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LTRA after low dose ICS 
 
The introduction of LTRA after ICS is potentially the most contentious and problematic of 
the differences between the two guidelines. BTS/SIGN continue the long-held view that low 
dose ICS should be followed by addition of long-acting beta-agonists (LABA) in line with 
international guidelines such as the Global Initiative for Asthma (GINA) (19). 
 
Head to head comparisons of ICS/LABA compared to ICS/LTRA have favoured ICS/LABA for 
effectiveness in adults (inconclusive in children) (20). However, the cost differential is 
substantial between generic LTRA and LABA so when NICE used a cost-effectiveness model, 
the results favour LTRA, even though (as NICE acknowledge) LABA is the more effective 
treatment.  
 
On a practical level, an increase in therapy from ICS alone to ICS/LABA, in most cases, only 
requires the name of the inhaler to be changed; the patient just continues using one inhaler 
as their preventer. Indeed, in the case of single maintenance and reliever therapy (MART), a 
single inhaler may be all that is required.  Patients given LTRA have to adapt to an oral 
therapy, taken only at night, potentially affecting adherence to the inhaled preventer 
therapy. Preferences (including cultural) for tablets or inhalers and the immediate clinical 
benefit experienced by the LABA may also influence adherence, as may additional 
prescription costs for the patient. 
 
The choice for clinicians will be prescribing LABA in a combination inhaler as the more 
effective first line add-on therapy (BTS/SIGN) or adopting the NICE strategy of trying the 
cheaper option of a LTRA which will be cost-effective for those in whom it works. It could, 
however, be more expensive if ineffective LTRAs are not withdrawn before LABAs are 
prescribed.  A pragmatic trial comparing add-on therapies found that a quarter of people 
commenced on LTRA switched to, or were given additional LABA; none switched from the 
LABA strategy (21).  
 
Additionally, a failure to gain asthma control may ultimately lead to avoidable attacks and 
associated costs through emergency attendances and even hospital admissions. (22). 
 
Another potential concern is losing the trust of the patient through the initial use of a cheap 
but often ineffective treatment in place of an effective simple regimen. 
 
Beyond combination therapy 
 
Both guidelines freely admit that evidence for optimal treatment of patients still 
uncontrolled after combination therapy is very limited. BTS/SIGN continue to document 
other treatment options (including specifically detailing effectiveness studies reporting the 
addition of Long-Acting Muscarinic Receptor Antagonists (LAMA)). NICE does not offer any 
practical guidance on what practitioners should do when patients are still uncontrolled on 
high dose ICS, LABA, LTRA and theophyllines, other than suggest seeking the help of an 
“asthma specialist”. The NICE guidance does not discuss advanced therapies such as anti IgE 
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monoclonal antibody, anti IL-5 monoclonal antibody or bronchial thermoplasty, all approved 
by NICE and widely used in severe asthma services across the UK.  
 
 
Maintenance and Reliever Therapy 
 
Adults 
Both guidelines state that there is evidence that a MART regime reduces the number of 
attacks in adults, but there is a discrepancy between the guidelines in the recommended 
target group.  NICE recommends a MART regimen for people with asthma “uncontrolled on 
a low dose of ICS/LABA, with or without an LTRA” with the caveat that the maintenance ICS 
dose should continue to be ‘low’ (as highlighted by the economic evaluation). BTS/SIGN 
advises considering a MART regimen for patients ‘who have a history of asthma attacks on 
medium dose ICS or ICS/LABA’.  
 
In day to day practice, decisions on inhaler regimens depend upon consultation between 
the physician and patient based on technique, compliance and convenience for the patient. 
The evidence reviewed in both sets of guidelines would suggest that a MART regimen is a 
viable option and discussion with the patient should inform which option to take. 
 
Children 
The NICE guideline recommends considering MART regimen in children and young people 
aged 5 to 16 on the basis of evidence from Bisgaard (22) that indicated fewer attacks in 
children using MART, although it is acknowledged that no MART combination is licensed for 
use in children at the time of publication.  
 
BTS/SIGN has not reviewed this evidence and in the absence of a licensed product, does not 
make a recommendation for use of MART in children.  
 
Supported self-management 
 
Both guidelines agree on the importance of supported self-management including providing 
clear written advice on actions to take if asthma control deteriorates.  Action plans should 
include advice on short-term increase (e.g. short-term quadrupling of dose) of ICS, when to 
commence oral steroids, and when to seek emergency medical advice.   Implementation is 
challenging.  Based on a search of the implementation literature (23), BTS/SIGN 
recommends a whole systems approach; NICE recommends research on ‘delivering an 
asthma self-management package’ 
 
Some other issues in managing asthma in children 
 
Categorising inhaled corticosteroids dosing and potency in children 
There are some discrepancies between the NICE and BTS/SIGN categorisation of inhaled steroid 
dosages for children. NICE have followed the GINA guidelines (19) and define ICS doses for children 
as low, moderate and high dose (NICE Guideline Chronic asthma management Table 3 (4)). BTS/SIGN 
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uses very low, low and medium categories and specifically defines doses of commonly used ICS 
preparations (BTS/SIGN Guideline Table 10 (2)). The age ranges used to define a child also differ. 
NICE defines children as under 16 years while for both BTS/SIGN and GINA adolescents over 12 years 
are considered with adults (in line with the inclusion criteria of many adult pharmacological studies).  
 
There is an important discrepancy in the summary tables categorising steroid potency (NICE 
Guideline Chronic asthma management Table 3(4); BTS/SIGN Guideline Table 10 (2)) with potential 
safety issues of which clinicians should be aware (see Table 1).   Fluticasone is usually regarded as 
twice as potent as beclometasone. However, in their dose equivalency table (NICE Guideline Chronic 
asthma management Table 3 (4)), NICE (and GINA) give the equivalent dose of the commonly used 
Fluticasone Propionate HFA as the same or higher than Beclometasone HFA; similarly, Budesonide 
DPI and Fluticasone DPI are categorised as being equipotent. The Summary of Product 
Characteristics in the Medical Compendium (24) clearly advises that “Prescribers should be aware 
that fluticasone propionate is as effective as other inhaled steroids approximately at half the 
microgram daily dose”; in line with this BTS/SIGN advise that, to avoid over-dosage, the dose of 
fluticasone should be half that of beclometasone (see Table 1 below; BTS/SIGN Guideline Table 10 
(4)). 
 
Table 1: Dose equivalency table: Children.  Comparing NICE, GINA and BTS/SIGN 
 
Guideline  Drug & Dose 
 Dose / day Beclometasone 
(HFA) 
Fluticasone FP  
(HFA) 
NICE Low 50-100μg 100-200μg 
Children <16 years Moderate >100-200μg >200-500μg 
 High >200μg >500μg 
    
GINA Low 50-100μg 100-200μg 
Children 6-11 years Moderate >100-200μg >200-500μg 
 High >200μg >500μg 
    
BTS/SIGN Very low 100μg 50μg 
Children <12 years Low 200μg 100μg 
 Medium 400μg 250ug 
 
One other important practical difference is that BTS/SIGN recommends that children on 
medium ICS dose ‘should’ be under the care of a specialist paediatrician for the duration of 
the treatment. NICE only recommends ‘considering’ seeking advice from a health care 
professional with expertise in asthma for children between 5 and 16 years who are on a 
moderate ICS dose with LABA and have uncontrolled asthma. 
 
Inhaler devices 
Choosing and using an inhaled device is a critical part of managing asthma, particularly for 
children. NICE acknowledges suboptimal inhaler technique as a possible reason for 
uncontrolled asthma and advises that inhaler technique should be observed and checked at 
every consultation. BTS/SIGN summarises the available evidence and gives good practice 
recommendations on device choice; NICE signpost a separate NICE document for further 
guidance (25). 
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Another point BTS/SIGN highlights is that generic prescribing of inhalers should be avoided, 
for children and adults, as this might lead to people with asthma being given an unfamiliar 
inhaler device which they are unable to use properly. 
 
Management in children under 5 years  
Children under 5 years are a particular problem for asthma management guidelines because 
the evidence base is limited or absent.  
 
There are two particular problems at this age. Firstly, there is a lack of good objective tests 
to guide either diagnosis or management in children under 5 years. Secondly, the pattern of 
asthma in preschool children is heterogeneous and different from adults. Wheezing/asthma 
attacks are triggered by viral infections (‘colds’) and often there are no asthma symptoms 
between attacks. This is the commonest pattern (‘phenotype’) up to three years of age after 
which interval symptoms typical of chronic asthma become more evident. Both NICE and 
BTS/SIGN note that many children under five with recurrent episodes of viral-induced 
wheezing do not go on to have chronic asthma. Neither guideline addresses the issue of 
what to do with the child who is having frequent wheezing attacks treated with short 
courses of oral corticosteroids, but who has no interval asthma symptoms.  
 
First-line preventer treatment in children under 5 with probable asthma and poor 
symptom control 
In young children with symptoms uncontrolled by intermittent reliever use in whom 
maintenance therapy is being considered, regular daily inhaled corticosteroid is the first-line 
preventer of choice although both BTS/SIGN and NICE acknowledge that the evidence base 
is limited. 
 
In these children, NICE recommends an 8-week trial of a paediatric moderate dose (‘Trial of 
treatment’). At the end of the 8 weeks, NICE advises stopping treatment and assessing the 
response and subsequent progress. If symptoms resolve on steroids but recur within 4 
weeks of stopping, maintenance low dose ICS should be started. If symptoms recur after 4 
weeks then a further repeat trial of 8 weeks moderate dose ICS is suggested. NICE’s 
recommendation to start at a paediatric moderate dose was driven by a need to be 
confident whether or not the symptoms were responsive to ICS. 
 
For BTS/SIGN, a trial of ICS treatment with careful objective evaluation of the response is an 
integral part of the diagnostic process at all ages, with a good response supporting a 
diagnosis of asthma. The recommended starting dose of ICS should be appropriate to the 
severity of the disease and should then be titrated to the lowest dose at which control is 
maintained (noting that this will result in a ‘trial of withdrawal’ in children whose symptoms 
do not recur). BTS/SIGN highlights that in many children who have symptoms only with 
colds ‘watchful waiting with review’ may be a useful strategy, at least initially. 
 
If asthma in children under 5 is uncontrolled on first line preventer, what next? 
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At this stage, both NICE and BTS/SIGN state that evidence is very limited. BTS/SIGN note 
that long acting bronchodilators are not licensed under 4 years and evidence comparing ICS 
+ LABA vs ICS + LTRA at this age is absent. Both NICE and BTS/SIGN recommend an LTRA in 
combination with low dose ICS as the next step. If that fails, NICE suggest stopping the LTRA 
and referring to a clinician with expertise in asthma.  
 
Conclusion 
 
In considering the areas where differences occur between the recommendations made in 
BTS/SIGN and NICE guidelines, it is clear that close scrutiny of the evidence base shows that 
there is often more in common between the guidelines than might appear at first glance. It 
is hoped that this examination of the differences highlighted in this article will assist 
clinicians in making decisions with their patients. 
 
Our understanding of asthma is evolving and our assessment of treatments must evolve 
with it. Further research to clarify the areas where data are currently limited or absent is 
urgently required in order that further updates can offer the best evidence based advice.  
 
 
References 
 
1. Scottish Intercollegiate Guidelines Network (SIGN) 50 handbook 
(http://www.sign.ac.uk/sign-50.html accessed 4/12/2017)  
 
2. BTS/SIGN British Guideline for the management of asthma, 2016, SIGN 153. 
(http://www.sign.ac.uk/sign-153-british-guideline-on-the-management-of-asthma.html 
accessed 4/12/2017) 
 
3. Asthma: diagnosis and monitoring of asthma in adults, children and young people.  NICE NG 
80, Methods, evidence and recommendations, November 2017 
(https://www.nice.org.uk/guidance/ng80/evidence/full-guideline-asthma-diagnosis-and-
monitoring-pdf-4656178047 accessed 4/12/2017) 
 
4. Chronic asthma management. NICE NG 80, Methods, evidence and recommendations, 
November 2017.  (https://www.nice.org.uk/guidance/ng80/evidence/full-guideline-chronic-
asthma-management-pdf-4656179345 accessed 4/12/2017) 
 
5. Asthma: diagnosis, monitoring and chronic asthma management, NICE NG80, November 
2017 (https://www.nice.org.uk/guidance/ng80 accessed 4/12/2017) 
 
6. Aaron, S.D., Vandemheen, K.L., FitzGerald, J.M., Ainslie, M., Gupta, S., Lemière, C., Field, S.K., 
McIvor, R.A., Hernandez, P., Mayers, I. and Mulpuru, S., 2017. Re-evaluation of diagnosis in 
adults with physician-diagnosed asthma. JAMA, 317(3), pp.269-279. 
 
7. José, B.P.D.S., Camargos, P.A.M., Cruz Filho, Á.A.S.D. and Corrêa, R.D.A., 2014. Diagnostic 
accuracy of respiratory diseases in primary health units. Revista da Associação Médica 
Brasileira, 60(6), pp.599-612 
 
 10 
 
8. Looijmans-Van den Akker, I., van Luijn, K. and Verheij, T., 2016. Overdiagnosis of asthma in 
children in primary care: a retrospective analysis. Br J Gen Pract, 66(644), pp.e152-e157 
 
9. Appendix Q Feasibility report: Asthma: diagnosis and monitoring guideline.  Primary care 
implementation feasibility project. 
(https://www.nice.org.uk/guidance/ng80/evidence/appendices-a-r-pdf-4656178048 
accessed 4/12/2017)  
 
10. Heneghan C, Glasziou P, Thompson M, Rose P, Balla J, Lasserson D, Scott C, Perera R. 
Diagnostic strategies used in primary care. BMJ 2009;338:b946 
 
11. Fitzpatrick, AM et al. Individualized therapy for persistent asthma in young children. J Allergy 
Clin Immunol 2016;138:1608-18 
12. Quanjer PH, Stanojevic S, Stocks J, Cole TJ. GLI-2012 All-Age Multi-Ethnic Reference Values 
for Spirometry www.ers-education.org/lrmedia/2012/pdf/266696.pdf  
 
13. Murray C et al.   Diagnosis of asthma in symptomatic children based on measures of lung 
function: an analysis of data from a population-based birth cohort study. Lancet Child 
Adolescent Health, 2017.   http://dx.doi.org/10.1016/S2352-4642(17)30008-1 
 
14. Shaw DE, Wilson E, Pavord ID.  Exhaled nitric oxide in asthma. Eur Respir Mon 2010; 49:32–
44. 
 
15. Harnan SE, Essat M, Gomersall T, Tappenden P, Pavord I, Everard M, Lawson R. Exhaled nitric 
oxide in the diagnosis of asthma in adults: a systematic review. Clinical & Experimental 
Allergy. 2017 Mar 1;47(3):410-29 
 
16. Karrasch S, Linde K, Rücker G, Sommer H, Karsch-Völk M, Kleijnen J, Jörres RA, Schneider A. 
Accuracy of FENO for diagnosing asthma: a systematic review. Thorax. 2017 Feb 1;72(2):109-
16 
 
17. Why asthma still kills, National Review of Asthma Deaths, 2015, RCP London 
 
18. Haahtela T, Tuomisto LE, Pietinalho A, Klaukka T, Erhola M, Kaila M, et al. A 10 year asthma 
programme in Finland: major change for the better. Thorax. 2006;61:663–70 
 
19. Global Initiative for Asthma, GINA, 2017. http://ginasthma.org/2017-gina-report-global-
strategy-for-asthma-management-and-prevention/   
 
20. Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long-acting beta2-agonists 
versus anti-leukotrienes for chronic asthma. Cochrane Database of Systematic 
Reviews 2014, Issue 1. Art. No.: CD003137. DOI: 10.1002/14651858.CD003137.pub5  
 
21. Price D et al.  Leukotriene Antagonists as First-Line or Add-on Asthma-Controller Therapy.  N 
Engl J Med 2011;364:1695-707 
 
22. Bisgaard H, Le Roux P, Bjamer D, Dymek A, Vermeulen JH, Hultquist C. 1 
Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric 2 
asthma. Chest. 2006; 130(6):1733-1743 
 
 11 
 
23. Pinnock H, Epiphaniou E, Pearce G, Parke HL, Greenhalgh T, Sheikh A, Griffiths CJ, Taylor 
SJC.  Implementing supported self-management for asthma: a systematic review of 
implementation studies. BMC Medicine 2015; 13:127 
 
24. The electronic Medicines Compendium: https://www.medicines.org.uk/emc/medicine/2913 
(accessed 1 November 2017) 
 
25. Guidance on the use of inhaler systems (devices) in children under the age of 5 years with 
chronic asthma. NICE technology appraisal guidance TA10 (2000). 
https://www.nice.org.uk/guidance/ta10 accessed 4/12/2017 
